Alignment Healthcare Third Quarter 2026 Earnings Call - ALIGNMENT HEALTHCARE INC

Financial Performance:

• Q3 2026 Revenue reached approximately $1.4 billion, up 37% year-over-year (YoY), driven by health plan membership of 301,200 (31% YoY growth).
• Adjusted Gross Profit was $142 million, with an Adjusted Medical Benefit Ratio (MBR) of 89.5%, a 240 basis point (bps) increase YoY due to claim volatility, aggressive provider appeals, and higher costs in skilled nursing and catastrophic cases.
• Adjusted SG&A was $120 million, representing an 8.9% of revenue ratio (improvement of 70 bps YoY), outperforming guidance by 90 bps; included a benefit from lower incentive compensation accruals.
• Adjusted EBITDA was $22 million, within the lower end of the original guidance range; Adjusted EBITDA margin was 1.6%.
• Operating cash flow for the first nine months was $158 million; ended the quarter with $743 million in cash, cash equivalents, and short-term investments.
• Funded leverage ratio was 2.4x trailing 12-month EBITDA.

Guidance and Future Outlook:

• Full-year 2026 guidance lowered: Revenue no less than $5.25 billion; Adjusted Gross Profit no less than $575 million; Adjusted EBITDA no less than $100 million.
• Q4 2026 guidance: Revenue no less than $1.32 billion; Adjusted Gross Profit no less than $104 million (implying 92.1% MBR); Adjusted EBITDA no less than negative $28 million.
• Guidance assumes continuation of Q3 elevated cost trends (appeals, disputes, SNF, catastrophic cases) and includes full burdening of current initiative costs without assuming near-term benefit realization.
• 2027 top-line growth target remains at least 20%, contingent on AEP results; management expects a balanced mix of HMO and C-SNP products.
• Management advises analysts not to annualize the Q4 MLR as a starting point for 2027, citing a "reset" and ongoing transformational benefits expected to improve performance in the new year.

Business Segments and Product Lines:

• Membership growth was broad-based, supported by strong retention and new additions; specific focus on expanding into San Antonio and Charlotte in 2027.
• California HMO contract (largest portfolio) received a 3.5-star rating for Payment Year 2028, below the company's 4+ star target in six of seven eligible plans; shortfall driven by HAADs and Part B measure misses.
• Strategic provider partnerships strengthened, including agreements with Hoag Memorial (Orange County) and Esrana (LA expansion).
• Claims system migration to "FACETS" completed in July; transition caused temporary volatility and higher claim trends, though appeals have stabilized since August.
• 2027 bid strategy involved recalibrating assumptions against current trends, de-emphasizing growth in certain markets/products, and expanding networks in others.

Market and Competitive Landscape:

• Competitive environment in D-SNP and C-SNP segments remains intense, with expected market consolidation and pressure on benchmarks in 2027.
• Management views the current environment as a catalyst for operational rigor, asserting confidence in winning in the "new world" despite tougher dynamics.
• Broker feedback remains positive regarding the California HMO despite the star rating decline, attributed to long-standing relationships and trust in management's commitment to fixing the issue.
• Industry-wide trends include increased provider use of AI for payment integrity, necessitating Alignment's investment in similar technological capabilities.

Risks and Challenges:

• Primary risk identified is elevated medical cost trends driven by a combination of system migration volatility, aggressive provider appeals/disputes, and higher spending in skilled nursing and catastrophic cases.
• California Star Rating (3.5 stars) poses a risk to payment year 2028 premiums and future bid positioning if not rectified by October 2026.
• Claims transition volatility led to unpredictability in prior year reserve development, though reserves for 2025 and prior dates of service are now considered well-positioned at ~99% run-out.
• Potential margin pressure from global cap models in 2028 is being mitigated by de-delegating inpatient utilization management (UM) back to the insurer.

Management Commentary and Tone:

• Tone was prudent, transparent, and accountable; management acknowledged the "messy" nature of the claims system conversion and the failure to meet CA star expectations but emphasized swift corrective action.
• Leadership expressed high confidence in the long-term clinical model and unit cost advantages, framing the current cost headwinds as temporary operational growing pains.
• Management stressed that addressing the Star Rating issue is a "cultural requirement" for the entire organization, not just a functional task.
• CEO John Cahill and CFO Jim Head emphasized discipline in forecasting, choosing to under-promise on the back half of 2026 to ensure delivery and set a strong foundation for 2027.

Analyst Questions and Answers:

• Claims System Impact: Clarified that the FACETS migration created timing volatility and a temporary spike in trends (peaking in July), which has since stabilized; however, guidance remains conservative assuming peak trends continue in Q4.
• 2027 Bidding: Confirmed bids were recalibrated product-by-product; some products will see reduced growth while others will accelerate, maintaining the 20% aggregate target based on improved risk adjustment and benefit design.
• Star Rating Remediation: Confirmed 3.5 stars in CA is primarily due to HAADs and Part B data issues; remediation involves increased "boots on the ground," provider member engagement, and closing HEDIS gaps. No immediate impact on 2027 AEP sales observed.
• Provider Delegation: Outlined a strategy to de-delegate inpatient UM from IPAs to gain control (80% complete) and focus future efforts on pre-service/outpatient management, particularly in non-California markets.
• Reserves: Confirmed Q3 reserve positioning is solid; prior year development variability was due to claims transition volatility, but current reserves are robust.

Other Key Points:

• Management confirmed they are not anticipating any material benefit from new payment integrity or clinical initiatives in the 2026 guidance, as costs are fully burdened but returns are not yet factored in.
• The company intends to enter two new states (San Antonio and Charlotte) in 2027 and is working to add further states by 2028, maintaining a strategy of scaling the care model nationally.
• Management reiterated that the C-SNP business is performing in-line with expectations despite the overall medical trend headwinds, validating the strategy of serving higher acuity populations.
• Incentive compensation benefits in Q3 helped improve SG&A ratio, but Q4 SG&A is expected to rise due to growth-related costs and AEP marketing expenses.